What drugs does 3D IMAGING DRUG make?

3D IMAGING DRUG has 3 FDA-approved drugs.

What therapeutic areas does 3D IMAGING DRUG focus on?

3D IMAGING DRUG focuses primarily on Oncology and Neurology.

← Back

Data updated: Jun 28, 2026

3D IMAGING DRUG

Generics

Oncology Neurology

3D IMAGING DRUG is a generic drug manufacturer focused on Oncology, Neurology.

2015

Since

Drugs

Trials

New Drugs (2yr)

Modality:

1 Small Molecules

3D IMAGING DRUG's Key Drugs

3D IMAGING DRUG's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

3D IMAGING DRUG's Recent FDA Approvals

New NDA/BLA approvals for 3D IMAGING DRUG over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

3D IMAGING DRUG's Therapeutic Areas

3D IMAGING DRUG's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 50%

1 drugs

Neurology 50%

1 drugs

3D IMAGING DRUG's Top Competitors

3D IMAGING DRUG's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Bristol-Myers Squibb big-pharma

Oncology, Neurology